CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
J Clin Pharmacol. 2015 Apr 28;
Authors: Fijal BA, Guo Y, Li SG, Ahl J, Goto T, Tanaka Y, Nisenbaum LK, Upadhyaya HP
Abstract
Atomoxetine, which is indicated for treatment of attention-deficit hyperactivity disorder (ADHD), is predominantly metabolized by the genetically polymorphic cytochrome P450 2D6 (CYP2D6). Based on identified CYP2D6 genotypes, individuals can be categorized into four phenotypic metabolizer groups as ultra-rapid, extensive, intermediate and poor. Previous studies have focused on observed differences between poor and extensive metabolizers, but it is not well understood whether the safety profile of intermediate metabolizers differs from that of ultra-rapid and extensive metabolizers. This study compared safety and tolerability among the different CYP2D6 metabolizer groups in the 12-week open-label phase of an atomoxetine study in adult patients with ADHD. Genotyping identified 1039 patients as extensive/ultra-rapid metabolizers, 780 patients as intermediate metabolizers, and 117 patients as poor metabolizers. Common (≥5% frequency) treatment-emergent adverse events were not significantly different between extensive/ultra-rapid and intermediate metabolizers (odds ratios were <2.0 or >0.5). Poor metabolizers had higher frequencies of dry mouth, erectile dysfunction, hyperhidrosis, insomnia, and urinary retention as compared to the other metabolizer groups. There were no significant differences between extensive/ultra-rapid and intermediate metabolizers in changes from baseline in vital signs. These results suggest that data from CYP2D6 intermediate and extensive/ultra-rapid metabolizers can be combined when considering safety analyses related to atomoxetine. This article is protected by copyright. All rights reserved.
PMID: 25919121 [PubMed – as supplied by publisher]
